Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2013

View Archived Issues

Novel CKId inhibitors show significant improvement in spatial memory in vivo

Researchers develop novel animal models of pediatric OP-induced SE

Alda-1 exerts protective effect against neuronal death in HE

uniQure develops novel gene therapies for HD

VASH1 as a biomarker of prognosis in RCC

Novel shRNA designed for Huntington's disease

Data presented from clinical study of NewGam IVIG in MCI

BioChaperone PDGF-BB to enter phase III development

Omeros identifies mechanism of action of its PDE7 inhibitors in addiction

Soligenix updates on ThermoVax vaccine thermostabilization technology

UCB and Five Prime Therapeutics enter collaboration

FDA recategorizes Meridian's illumigene tests for Streptococcus

Focus on carbapenem-resistant Enterobacteriaceae: need for action

Millennium Pharmaceutical presents new agents for cancer

Scientists at Bayer disclose novel BRD4 ligands

Amakem prepares new ROCK inhibitors

Otsuka Pharmaceutical divulges novel agents for bacterial infections

Hybrigenics synthesizes new USP7 inhibitors

Purdue Pharma discloses new Na(v)1.7 blockers

Biotron announces preliminary results from human trial of BIT-225

Novo Nordisk completes phase I study of new oral insulin

Acasti Pharma reports preliminary data from CaPre trial

First patients dosed in proof-of-concept trial of ALD-403

NX-1207 trial receives third positive safety review

BioMarin reports phase I/II data for BMN-701 in Pompe's disease

Merrimack Pharmaceuticals completes enrollment in a phase II study of MM-121

Pluristem Therapeutics gives update on study of PLX cells in muscle injury

BioLineRx to discontinue CLARITY trial following interim analysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...